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a b s t r a c t
In recent years, the treatment of locally-advanced and metastatic cervical cancer has
improved greatly due to the introduction of targeted therapies, new chemotherapy combi-
nations, and emerging treatments. Candidates for potentially curative treatment are those
patients with good functional status without associated comorbidities. Numerous trials
have demonstrated that chemotherapy prolongs survival versus supportive care alone. In
addition, polychemotherapy schemes are superior to single agent regimens. Targeted molec-
ular agents have proven beneficial in the treatment of cervical cancer. Second-line treatment
should be considered standard practice in patients with good functional status. Finally, given
the poor survival outcomes in patients with metastatic disease, participation in clinical
studies should always be considered the best option.
© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
1. Background
Cervical cancer is one of the leading causes of morbidity
and mortality worldwide, despite efforts to improve treat-
ment outcomes. It is the fourth most common cancer, with
a mean incidence rate of 9.0 cases per 100,000 persons in
developed countries and 17.8 cases/100,000 in developing
countries. Cervical cancer is closely associated with human
papilloma virus (HPV) infection. Nearly 80% of cervical cancer-
related deaths occur in low income countries with inadequate
screening measures.1,2 The treatment of early stage disease
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includes surgery and radiotherapy. The standard of care for
locally advanced disease is radiotherapy in combination with
cisplatin-based chemotherapy and this treatment may be
curative in patients with limited metastatic involvement.
Prior to taking any therapeutic decisions, patient’s clinical
stage must first be determined according to the classification
systems proposed by the International Federation of Gynecol-
ogy and Obstetrics and the AJCC (American Joint Committee
on Cancer). It is essential to determine whether the disease
is curable or not as this will have an impact on the treatment
decision. Patients with incurable disease may be candidates
for palliative care. At diagnosis, most patients (60–85%) have
https://doi.org/10.1016/j.rpor.2018.09.002
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advanced disease (clinical stage III or IV), including distant
metastatic disease located primarily in the supra- and infra-
diaphragmatic nodes and/or to the bones, lungs, or liver.
The development of targeted therapies in recent years has
increased the limited treatment options for this aggressive
disease.3
2. General aspects
The standard of care in most cervical cancers involves
systemic platinum-based chemotherapy with concomitant
radiotherapy. This combined modality has proven supe-
rior to radiotherapy alone for local and metastatic control,
with better outcomes in terms of disease-free survival (DFS)
and overall survival (OS). However, the use of concomitant
chemoradiotherapy implies increased toxicity (both gastroin-
testinal and hematological), although this is considered
manageable.
In early stage cervical cancer (i.e., clinical stage IA tumors
with <6% chance of presenting pelvic or para-aortic nodal
involvement), the treatment of choice is surgery. The selection
of adjuvant therapy will depend on the risk of relapse: patients
with a high risk of relapse – defined as presenting one or more
of the following factors: positive pelvic nodes, parametrial
invasion, positive surgical margins (parametrial/vaginal), and
a probability of recurrence of 50–60% – require concomitant
chemoradiotherapy.4
Patients with locally advanced disease (clinical stages IB2 to
IVA) benefit from concomitant chemoradiotherapy. The bene-
fits of concomitant therapy have been proven in five phase III
studies, for more than a decade.
The first study is GOG 085 trial, Whitney et al. (randomized
comparison of fluorouracil plus cisplatin versus hydroxyurea
as an adjunct to radiation therapy in stage IIB–IVA carcinoma
of the cervix with negative para-aortic lymph nodes)5; 76 (43%)
of 177 patients in the cisplatin/FU group had disease progres-
sion, whereas 101 (53%) of 191 in the HU group had disease
progression. The progression free survival (PFS) was statisti-
cally significant favoring the CF regimen (p = .033).
The RTOG 90-01 trial, Morris et al. (pelvic radiation with
concurrent chemotherapy compared with pelvic and para-
aortic radiation for high-risk cervical cancer),6 the five-year
survival rates were 73% and 58% in the combined therapy and
the radiotherapy (RT) alone arms, respectively (p = .004). Five-
year cumulative disease-free survival rates were 67% and 40%
in the combined therapy and RT groups, respectively (p < 001).
The degree of adverse events was comparable for both treat-
ment groups and, although the rates of hematologic effects
were higher in the combined therapy group, these toxicities
were reversible.
In the SWOG 8797 trial (GOG 109),7 Peters et al., the PFS
and OS are significantly improved in the patients receiving
chemotherapy (CT). The PFS at 4 years is 63% with RT and 80%
with RT-CT. The OS rate at 4 years is 71% with RT and 81%
with RT-CT. Grades 3 and 4 hematologic and gastrointestinal
toxicity were more frequent in the RT-CT group, but reversible.
In the four trial, GOG 120, for Rose PG (concurrent cisplatin-
based radiotherapy and chemotherapy for locally advanced
cervical cancer),8,9 both groups that received cisplatin had
longer PFS than the group that received hydroxyurea alone
and the OS rate was higher in these groups as well (relative
risks of death: 0.61 and 0.58, respectively).
In the fifth trial, the GOG 123 trial by Keys, (cisplatin,
radiation, and adjuvant hysterectomy compared with radia-
tion and adjuvant hysterectomy for bulky stage IB cervical
carcinoma),10 the rates of PFS and OS were significantly higher
in the combined therapy group at 4 years. The combined group
had higher frequencies of transient grade 3 and 4 adverse
hematologic effects (21% vs. 2% in RT group) and adverse gas-
trointestinal effects (14% vs. 5%, respectively).
All five of these studies have shown an improved OS and
PFS if platinum was used with concomitant chemoradiother-
apy with an absolute benefit of approximately 10–13% (Table 1).
Therefore, concomitant CT and RT should be considered for all
patients with cervical cancer. In Green et al. metaanalyses11
included 4580 randomized patients, with 2865–3611 patients
available for analysis (61–75%). Cisplatin was the most fre-
quent chemotherapeutic agent and the benefit in PFS and OS
was 16% and 12%, respectively, in this metaanalysis.
In a study conducted by Dueñas-González et al., 12 gem-
citabine was administered concomitantly with radiotherapy
followed by weekly adjuvant gemcitabine and cisplatin, result-
ing in a 9% improvement in OS at 3-years versus standard care
(concurrent cisplatin and radiation), with increased but still
manageable hematological toxicity.
3. Adjuvant treatment in advanced disease
The OUTBACK randomized phase III trial, active, not recruit-
ing, will evaluate adjuvant CT with paclitaxel and carboplatin
after CT-RT with cisplatin as primary treatment compared
with chemoradiation alone, on stage IB1 and positive nodes
and IB2, II, IIIV or IVA. In this trial, the purpose of using poly-
chemotherapy is to work in different ways to stop the growth
and division of tumor cells through different mechanisms.13
The spatial cooperation is effective in cervical carcinoma.
The interaction between RT and CT is used to improve loco-
regional control of the disease. There have been described
several mechanisms of interaction among those maneuvers. It
has been demonstrated to cause the inhibition of DNA repair,
but other effects such as cell/cycle synchronization, increased
apoptosis, and inhibition of tumor cell proliferation are not
clearly proven.14,15
Different data suggests, however, that the combined use
of cisplatin and radiation therapy results in a higher level of
tumoral cells killed by independent ways, additive toxicities
and not precisely because of radiosensitization.16
3.1. Complications of treatment
Commonly acute effects of pelvic RT include diarrea and blad-
der irritation that usually are self-limited and the late effects
included: recto-sigmoid complications, small intestine com-
plications, genitourinary and vaginal complications in a 10%
rate of major sequelae. The gastrointestinal tract is the most
frequent late complication of RT alone.17
Concurrent treatment with CT-RT results in gastroin-
testinal and hematologic toxicity, principally. In Green
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Table 1









Radiation alone + Hysterectomy EBRT 45 Gy/1.8 Gy/day
BT LDR 75 Gy Point A
67% 74%
CDDP 40 mg/m2 weekly for 6




526 IIB–IVA CDDP 40 mg/m2 at weeks
1–6 + RT
EBRT stage IIB: 40.8/1.7 Gy/day
stage II–IVA: 51 Gy/1.7 Gy/day
67%
CDDP 50 mg/m2 on days 1 and
29 + 5FU 4 g/m2 as 96-h
infusion, on days 1 and
29 + Hydroxyurea 2 g/m2 orally
twice weekly at weeks 1–6 + RT
BT 40 Gy (Point A) LDR
total Point A: 80–81 Gy
paramietrial boost to 55–60 Gy
64%
Hydroxyurea 3 g/m2 orally









CDDP 75 mg/m2 4 h
infusion + 5FU 4 g/m2 96 h
infusion days 1–5 for 3 cycles
every 21 days + RT pelvis
EBRT 45 Gy/1.8 Gy/day,
BT ≥40 Gy LDR
total Point A: ≥85 Gy;
parametrial boost to 55–60 Gy
61% 67% 85% 20%




385 11B–III Hydroxyurea 80 mg/kg orally
twice weekly at weeks 1–6 + RT
EBRT: stage IIB: 40.8/1.7 Gy/day;
stage II–IVA: 51 Gy/1.7 Gy/day
BT: 40 Gy (Point A) LDR,
57%
5-FU 1000 mg/m2/day on 2, 3, 4,
5, 30, 31, 32 and 33 + CDDP
50 mg/m2 day 1 and 29 + RT
total Point A: 80–81 Gy;




259 IB-IVA CDDP 40 mg/m2 weekly at 6
doses + RT
EBRT: 45 Gy/1.8 Gy/day,
BT Point A dose of 35 Gy,






268 IA2, IB, IIA
Post-OP
CDDP 70 mg/m2 + 5FU 96 h
1000 mg/m2 for 4 cycles + RT
EBRT 49.3 Gy/1.7 Gy/day
+/− para aortic irradiation
80% 81%





Cisplatin at 40 mg/m2 every
week × 6 + RT + hysterectomy
EBRT 50 Gy/2 Gy/day
BT after hysterectomy in
selected cases
55%
Gemcitabine at 125 mg/m2 plus
cisplatin at 40 mg/m2 every
week × 6 + RT + hysterectomy
77%
EBRT, external beam radiation therapy; BT, brachytherapy; PFS, progression free survival; OS, over all survival; PCR, pathologic complete response.
metaanalysis,11 the combined modality results in acute tox-
icity hematological and was severe or life-threatening in
more patients in the CT-RT group than in the control group
(neutropenia, 16% vs. 8%; platelets, 1.5% vs. 0.2%). Grade
3 or 4 gastrointestinal toxicity was also greater in the CT-
RT group than in the control group (9% vs. 4%). The late
toxicity was defined as toxicity beginning 42–90 days after
completion of radiation. The main tissues affected by late
toxicity were the bladder and gastrointestinal tract, with
no evidence of differences between the treatment groups.
A thromboembolic complications were noted in 16.7% of
48 patients who received chemoradiation, the routine use
of erythropoietin increased incidence of thromboembolic
complications.18
Actually, the use of intensity modulated radiation therapy
(IMRT) could be to limit hematologic toxicity, and the use of
coloning-stimulating factors.19,20
4. Systemic treatment in patients with
distant metastasis or recurrent/persistent
disease
At diagnosis, most patients with cervical cancer present with
locally advanced or metastatic disease, which explains why
mortality rates (16% at 5 years in patients with metastatic
disease) are so high in this patient population.21 These
suboptimal outcomes have led to a search for new strate-
gies, including modified CT schemes, targeted therapy, and
immunotherapy.
The objectives of treatment are to control or delay the
onset of symptoms, improve or maintain quality of life, and
to prolong survival. In clinical trials, mean survival ranges
from 9 to 13 months. However, outcomes have improved
in recent years due to the growing use of targeted therapy.
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Indications for systemic treatment include: clinical stage
IVB and recurrent or persistent disease. Treatment options
are currently based on the functional status of patients,
with a range of possible CT regimens, including single-agent
schemes, doublets, or even triplets.
Many chemotherapeutic agents are active in cervical can-
cer, including platinum-based agents (cisplatin, carboplatin),
taxanes (paclitaxel), topotecan, vinorelbine, gemcitabine, ifos-
famide, as well as other agents, including the targeted therapy
bevacizumab.22 Although all these medications are effective in
palliating symptoms, the duration of response is usually less
than 4 months. Objective response rates are better in non-
irradiated areas and in chemotherapy-naive patients.
4.1. Single-agent chemotherapy
Cisplatin administered at a dose of 50 mg/m2 every three
weeks achieves response rates ranging from 20% to 38%, with
a mean survival of 6–7 months.23 Other compounds such
as carboplatin, paclitaxel, ifosfamide, and topotecan offer
similar results. The impact of palliative CT on survival has
been demonstrated in several randomized trials of CT versus
palliative care. Agents such as mitomycin C, irinotecan, gem-
citabine, and vinorelbine present response rates ranging from
8% to 17%; in non-epidermoid histologies, response rates are
4.5% for gemcitabine, 31% for paclitaxel, and 7.1% for vinorel-
bine. The median response to paclitaxel is 4.8 months.23
4.2. Doublet or triplet chemotherapy
Compared to cisplatin monotherapy, the addition of paclitaxel
and/or topotecan yields better treatment response rates and
OS.
The phase III GOG 169 trial24 compared cisplatin with
or without paclitaxel in patients with stage IVB recurrent
or persistent cervical cancer. Despite prior treatment with
concomitant CT-RT, the patients in the trial were stage IVB.
Patients received cisplatin at a dose of 50 mg/m2 with or with-
out paclitaxel (135 mg/m2) every 3 weeks for six cycles. The
response rate in the single-agent group was 19% versus 36%
in the combined group (p = 0.002), with a median PFS of 2.8
versus 4.8 months (p < 0.001), respectively. The authors con-
cluded that the combination of cisplatin plus paclitaxel was
superior to cisplatin alone in terms of response rates and
PFS.24
The GOG 179 trial25 randomized patients to cisplatin with
or without topotecan. Cisplatin administered at doses of
50 mg/m2 every 3 weeks was compared to cisplatin 50 mg/m2
on day 1 and topotecan 0.75 mg/m2 on days 1–3 every 3
weeks; a third arm received methotrexate, vinblastine, dox-
orubicin, and cisplatin (this third arm was closed early due
to treatment-related deaths). Patients in the doublet arm pre-
sented significantly better outcomes than those who received
cisplatin alone, with a median OS of 9.4 versus 6.5 months
(p = 0.017), median PFS of 4.6 versus 2.9 months (p = 0.014), and
response rates of 27% versus 13%.25
Given these results, a subsequent study was conducted to
determine the best cisplatin doublet. A total of 513 patients
were randomized to four different treatment groups: (1) pacli-
taxel 135 mg/m2 24 h infusion with cisplatin 50 mg/m2 on day
2 every 3 weeks (reference arm); (2) vinorelbine 30 mg/m2
on days 1 and 8 plus cisplatin 50 mg/m2 on day 1 every 3
weeks; (3) gemcitabine 1000 mg/m2 on days 1 and 8 plus
cisplatin 50 mg/m2 on day 1 every 3 weeks; or topotecan
0.75 mg/m2 on days 1–3 and cisplatin 50 mg/m2 on day 1
every 3 weeks. The paclitaxel/cisplatin regimen showed a bet-
ter overall median survival than the other regimens.26 Other
studies have also shown a treatment response, even without
combining platinum-based chemotherapy. A phase II trial that
included paclitaxel at a dose of 175 mg/m2 on day 1 combined
with topotecan 1 mg/m2 on days 1–5 of a 21-day cycle showed
a 54% response rate, with PFS and OS of 3.7 and 8.6 months,
respectively.27
Based on the data described above, the combination of cis-
platin and paclitaxel is considered the first-line treatment of
choice. Other options include cisplatin combined with topote-
can or gemcitabine, or the combination of paclitaxel and
topotecan.
4.3. Second line systemic treatment
Second-line therapies in cervical cancer show response rates
ranging from 0% to 14%, with a median progression of 2–4
months.23 Given these poor results, the emergence of new
molecular therapies represent a promising new approach in
the search for new opportunities for targeted treatment.
4.4. Targeted therapy
Targeted therapies have also been investigated in the treat-
ment of advanced, persistent or recurrent disease. The GOG
227C trial28 evaluated bevacizumab, a monoclonal antibody
directed against the vascular endothelial growth receptor A
(VEGF-A). This phase II study evaluated patients who had pre-
viously received 1–2 lines of systemic CT. The median duration
of the response was 6.2 months, with PFS and OS, respectively,
of 3.4 and 7.2 months.28
A subsequent phase III trial (GOG 0240)29 evaluated four
arms: cisplatin and paclitaxel with or without bevacizumab
and topotecan and paclitaxel with or without bevacizumab.
The combination of topotecan and paclitaxel was not supe-
rior to cisplatin and paclitaxel. Importantly, the addition of
bevacizumab improved mean PFS by >2 months (8.2 versus
5.9 months) and mean OS by nearly 4 months compared to
CT alone (17.0 vs. 13.3 months). Bevacizumab was associated
with an increased incidence of grade 2 (G2) or higher hyperten-
sion, G3 or higher thromboembolic events, and G3 or higher
gastrointestinal fistulas. Health-related quality of life was not
significantly worse compared to CT alone. The combination
of cisplatin, paclitaxel and bevacizumab is the new standard
of care in the treatment of advanced and recurrent cervical
cancer.29
4.5. Immunotherapy
The causal relationship between HPV infection and cervical
cancer is well established, and HPV infection is involved in
80–90% of all cervical cancers.30,31 HPV evades the immune
system through increased PD-L1 (programmed death ligand
1) expression, thus allowing the virus to remain in the body
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and to potentially develop a tumor. Nivolumab, an anti-PD-1
monoclonal antibody, has shown antitumor activity in several
cancer types and could also be active against gynecological
tumors associated with viral infections.32
The CheckMate 358 trial is an ongoing phase I/II trial of
nivolumab in patients with virus-associated tumors to deter-
mine the efficacy and safety of this drug in recurrent or
metastatic cervical, vaginal, and vulvar cancers.33 Patients in
that study receive a dose of 240 mg of nivolumab monother-
apy every two weeks until disease progression or unacceptable
toxicity. Interim findings indicate a 20.8% response in patients
with PD-L1 expression and a stable disease in 70% of patients;
median OS rates have not yet been determined.
4.6. Human papilloma virus
Another approach to the treatment of HPV-related cancers is
vaccination. The innate immune response is responsible for
limiting the viral load and plays an important role in eliminat-
ing HPV. However, in some cases, the host’s immune response
is unable to control the infection. In such cases, vaccination
can induce a notable and sustained immune response, as
evidenced by a rapid rise in antibodies. High serum levels cor-
respond to high levels of antibodies in the cervix. Persistent
HPV infection due to an inadequate or non-existent immune
response can lead to cancer.34,35
The ADXS11-011 immunotherapy vaccine (Advaxis) is
based on live attenuated Listeria monocytogenes bioengineered
to secrete HPV-16-E7 (a fusion protein). Phase II studies show
that Advaxis administered alone or with cisplatin demon-
strate anti-tumor activity in recurrent or persistent cervical
cancer, with good tolerance.36 The phase III ADXS11-011 trial
involving patients with locally-advanced, high-risk cancer
treated with adjuvant Advaxis after chemo-radiotherapy (at
weeks 3, 6 and 9 post CT-RT and then every 8 weeks for 1 year)
versus placebo is currently ongoing.37
Other therapeutic platforms include local immunomodula-
tors, recombinant vectors (vaccinia virus or L. monocytogenes),
adaptive immunotherapy, and gene transfer. GN-00101 is a
therapeutic vaccine consisting of a fusion protein containing
an Mycobacterium bovis BCG heat shock protein (Hsp65) cova-
lently linked to the entire sequence of HPV16-E7. This vaccine
has shown an effective induction of tumor regression and
has been associated with activity against anal and cervical
intraepithelial neoplasia, genital warts, and recurrent papil-
lomatosis. Maldonado et al. found a marked post-vaccination
increase in CD8+ T cells infiltrating the tumor; this approach
may achieve a better immune response through anti-PD1
antibodies.38
5. Other agents
5.1. Conjugated monoclonal antibodies
Tisotumab vedotin is a conjugated monoclonal antibody com-
posed of a human tissue factor (TF) and an antimicrotubule
agent. This antibody targets the TF, a transmembrane pro-
tein involved in angiogenesis and cell survival, which may
be abnormally expressed in several different solid tumors,
including cervical cancer. With respect to the mechanism
of action, the tumor cell binds to the monoclonal antibody
through the TF, internalizing the antibody intracellularly, thus
leading to enzymatic degradation and intracellular release
of the antimicrotubule agent, which induces cell death by
altering the microtubule and by release into the microenvi-
ronment.
A phase IIA 9310 trial (NCT02552121) evaluated tisotumab
vedotin in patients with recurrent or persistent metastatic
cervical cancer after first line systemic therapy. A 30-patient
cohort received a dose of 2 mg/kg of weight every 3 weeks until
progression and/or unacceptable toxicity. The response rate
was 32%, with a median survival of 8.3 months and an accept-
able toxicity profile. The most common adverse event was
conjunctivitis, but this was controlled through a mitigation
plan.39
5.2. Ribonucleotide reductase (RNR) inhibitors
The HPV oncoproteins, E6 and E7, activate RNR, which is
necessary for the synthesis of deoxyribonucleotide acids.
High levels of RNR are associated with a worse response
to concomitant CT-RT in patients with cervical cancer. For
this reason, RNR inhibitors, such as hydroxyurea, have been
used to improve response to concomitant CT-RT in locally
advanced cancer. The combination of Triapine (an RNR
inhibitor) + concomitant CT-RT based on platinum is currently
being under investigation. A phase I study found that the
combination was well-tolerated. A phase II trial conducted
by Kunos et al. evaluated Triapine + weekly cisplatin + RT in 24
treatment-naive patients (stages IB2–IIIB). The 3-year DFS in
that trial was 80%.40
5.3. PARP inhibitors
PARP is activated in response to DNA damage. Blocking this
enzyme prevents repair of single-strand breaks, thus lead-
ing to a build-up of these breaks. The inhibitors can trap the
PARP1 and PARP2 enzymes at the site of DNA damage, thereby
blocking DNA replication and causing cell death. Several stud-
ies have shown that PARP inhibitors act synergistically with
RT to increase radiosensitivity. A phase I trial evaluated ola-
parib + carboplatin. An ongoing phase I/II trial is evaluating
the combination of veliparib + carboplatin + paclitaxel, with
results still pending.23
6. Conclusions
In recent years, the treatment of locally-advanced and
metastatic cervical cancer has improved greatly due to the
introduction of targeted therapies, new CT combinations, and
emerging treatments. Systemic treatment with CT prolongs
the survival of treated patients versus those who receive only
supportive care.
In addition, polychemotherapy schemes are superior to
single agent regimens. Targeted molecular agents in combi-
nation with RT have proven beneficial in the treatment of
cervical cancer. Second-line treatment should be considered
a standard practice in patients with a good functional status.
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Paliation symptoms, oligo-metastatic disease control, mini-
mum cost of toxicity are an acceptable and desirable goal
in these patients. Finally, given the poor survival outcomes
in patients with metastatic disease, participation in clinical
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